User shared 8-month progress with finasteride 0.5 mg 4 times a week and gluten-free diet for 5 months, improving hair loss. Plans to try microneedling soon.
Topical spironolactone is discussed for hair loss treatment, with mentions of DIY solutions and dermatologist compounding. Users inquire about regrowth and sourcing the treatment.
User reports almost 2 months on DUT and MIN for hair loss with positive results. Treatment includes 0.5mg dut (morning), 5mg oral min (night), and vitamin D and B12 supplements.
Some people have low sulfotransferase enzyme levels, affecting their response to minoxidil. Lifestyle factors, genetics, and diet, like MSM intake, might influence these enzyme levels.
The conversation is about exploring alternatives for hair loss treatment, specifically ds laboratory revita shampoo and nanoxidil, with the user currently using microneedling. The user is considering these options due to fewer side effects compared to other treatments.
Topical finasteride is considered safer for the liver than oral finasteride due to less systemic absorption, but regular liver function tests are advised. The user is concerned about liver health due to a history of NAFLD and is exploring topical finasteride as a safer alternative.
Hair loss discussion includes topical Spironolactone's effectiveness and minimal side effects. Community members share personal experiences and opinions on its use.
Potential success with the hair loss treatment Pyrilutamide, and possible group buying opportunities for it along with other treatments such as Finasteride and Minoxidil.
A phase 3 trial for Breezula (clascoterone solution) to treat male pattern hair loss has been listed, with 726 participants and a completion date of January 2025. Other treatments mentioned include Aneira Pharma's combination of minoxidil and latanoprost, Triple Hair's combination of minoxidil, latanoprost, and finasteride, and a new microneedling and LLLT device called StimuSIL.
Chinese company gets green light for Pyrilutamide Phase II trial for androgenetic alopecia. Androgen receptors downregulate in androgen deficient environments.
Users discuss the release of Pyrilutamide 1% outside China and its potential effectiveness compared to 0.5%. They also mention using Minoxidil, Finasteride, and RU58841 for hair loss treatment.
The user is confused about the pricing and concentration of pyrilutamide powder for hair loss treatment. They calculate that 500mg of pyrilutamide can make ten 1ml applications of a 5% solution, costing $119.
The user is experiencing worsening hair loss despite undergoing monthly injectable finasteride, clay masks, laser therapy, and microneedling. They are concerned about severe shedding in areas not typically affected by male pattern baldness and are considering seeking a second opinion.
Redensyl, a hair loss treatment that has been claimed to be 80% more effective than minoxidil, but users have not experienced any results from using it.
A 30-year-old female with telogen effluvium and androgenetic alopecia is using spironolactone, oral minoxidil, vitamin D, iron sulfate, and a hairmax laser band. She seeks recommendations for a dermastamp or derma roller, advised to use no higher than 0.5 mm.
Scube3, a potential hair loss treatment, is unlikely to be released because it was given to a startup company, Amplifica, which may go bankrupt and fail to bring the treatment to market. Amplifica is prioritizing other treatments over Scube3, which could lead to financial loss and the end of Scube3's development.
A user is trying 2-deoxy-D-ribose with distilled water for hair growth, observing new hair and skin pigmentation changes. Others compare it to Minoxidil, expressing interest and caution about its effectiveness and safety.
The user is using a regimen for hair loss that includes topical and oral minoxidil, finasteride, a Musley holistic formula, homemade oil, and scalp massages. They are questioning if there is any progress in hair regrowth.
The conversation discusses hair loss treatments, mentioning minoxidil, finasteride, RU58841, VDPHL, GT20029, and follicle cloning as potential solutions. It also reveals that the discussion about PP405 was an April Fool's joke.
TGF-B affects hair growth, both causing stem cell division and death depending on amounts. Amplifica's treatment injects Scube3 to increase TGF-B for hair growth.
The conversation discusses the potential of PP405 as a hair loss treatment, with some users expressing skepticism and others hopeful about its development. There is also mention of other treatments like Minoxidil, Finasteride, and Pyrilutamide, with users debating the effectiveness and safety of self-experimentation versus waiting for clinical trial results.
A 12-year-old diagnosed with alopecia shares their experience and current treatments, including Dermovate, an unnamed cream, and liquid iron. The community offers support and encouragement.
PP405 shows initial promise for treating androgenetic alopecia, with safety confirmed in early trials, but skepticism remains due to limited data. Further trials are needed to determine its true efficacy and potential market impact.
Pelage Pharmaceuticals is developing PP405, a topical treatment for hair growth, currently in Phase 2a trials. There is skepticism about the company's claims, and no fast-tracking approval timeline has been detailed.
A 15-year-old is seeking advice on preventing hair loss, identified as Norwood level 2, and wants tips for growing long hair. They have consulted a trichologist who recommended specific shampoos.
An 18-year-old male using minoxidil and finasteride is experiencing increased hair loss, possibly due to a shedding phase from finasteride. He also takes zinc, magnesium, calcium, and vitamin C, and is concerned about hair loss from his temples.
A user noticed increased hair loss after taking B12 supplements for two months, with B12 levels rising to 1500. They are seeking help as other tests show normal levels of minerals and vitamins.